Allison Thibodeau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Allison Thibodeau has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Emily A. Rosen
Fred Hutchinson Cancer Center
2 shared publications - Masumi Ueda Oshima
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
2 shared publications Catherine Liu
Fred Hutchinson Cancer Center
1 shared publication- Catherine Liu
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington
1 shared publication - Cynthia K. Wallace
Fred Hutchinson Cancer Center
1 shared publication Elizabeth M. Krantz
Fred Hutchinson Cancer Center
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e368
Yield of a multiplexed gastrointestinal polymerase chain reaction panel for evaluation of diarrhea in hospitalized patients with cancer: a diagnostic stewardship opportunity
Background: Multiplexed polymerase chain reaction gastrointestinal panels (GIPs) include mostly community-acquired pathogens. Diagnostic yield of GIPs for detection of non- Clostridioides difficile targets in hospitalized patients with cancer with community versus hospital-onset diarrhea is not well defined. Methods: This cross-sectional study included stool tests from hospitalized adults with a cancer diagnosis from July 2021 to May 2025. Our center recommends a GIP primarily for patients with community-onset diarrhea and stand-alone C. difficile testing for hospital-onset diarrhea. Generalized estimating equations with Poisson regression were used to estimate the prevalence ratio (PR) of detecting ≥1 non- C. difficile target after hospital day (HD) 3 compared to HD 1–3. Results: Among 1,433 GIPs from 1,127 patients, 468 (33%) were ordered after HD 3. Most GIPs were among patients with hematologic malignancies (794/1,433; 55%) and of those tests 352/794 (44%) were ordered after HD 3. Among all GIPs, C. difficile and norovirus were detected most frequently (16% and 6%, respectively). A non- C. difficile target was detected after HD 3 on 49/468 GIPs (10%), compared to 146/965 (15%) GIPs on HD 1–3 (adjusted PR 0.73; 95% CI [0.53–1.00]; P = .053). Among 49 GIPs after HD 3 detecting ≥1 non- C. difficile target, 19 tests were ordered for new-onset diarrhea and only 5 of these patients received intentional antimicrobial therapy in response to the GIP result. Conclusions: The added diagnostic yield for detecting ≥1 non- C. difficile target by GIP in patients with cancer and hospital-onset diarrhea is limited and supports restricting GIP ordering after HD 3 on oncology units.
- 12 November 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e368
Open AccessYield of a multiplexed gastrointestinal polymerase chain reaction panel for evaluation of diarrhea in hospitalized patients with cancer: a diagnostic stewardship opportunity
Background: Multiplexed polymerase chain reaction gastrointestinal panels (GIPs) include mostly community-acquired pathogens. Diagnostic yield of GIPs for detection of non- Clostridioides difficile targets in hospitalized patients with cancer with community versus hospital-onset diarrhea is not well defined. Methods: This cross-sectional study included stool tests from hospitalized adults with a cancer diagnosis from July 2021 to May 2025. Our center recommends a GIP primarily for patients with community-onset diarrhea and stand-alone C. difficile testing for hospital-onset diarrhea. Generalized estimating equations with Poisson regression were used to estimate the prevalence ratio (PR) of detecting ≥1 non- C. difficile target after hospital day (HD) 3 compared to HD 1–3. Results: Among 1,433 GIPs from 1,127 patients, 468 (33%) were ordered after HD 3. Most GIPs were among patients with hematologic malignancies (794/1,433; 55%) and of those tests 352/794 (44%) were ordered after HD 3. Among all GIPs, C. difficile and norovirus were detected most frequently (16% and 6%, respectively). A non- C. difficile target was detected after HD 3 on 49/468 GIPs (10%), compared to 146/965 (15%) GIPs on HD 1–3 (adjusted PR 0.73; 95% CI [0.53–1.00]; P = .053). Among 49 GIPs after HD 3 detecting ≥1 non- C. difficile target, 19 tests were ordered for new-onset diarrhea and only 5 of these patients received intentional antimicrobial therapy in response to the GIP result. Conclusions: The added diagnostic yield for detecting ≥1 non- C. difficile target by GIP in patients with cancer and hospital-onset diarrhea is limited and supports restricting GIP ordering after HD 3 on oncology units.
- Open Access
- 20 January 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e826-e834
Diagnostic Yield of Repeat Blood Cultures and Risk Factors for Bloodstream Infection in Persistent Febrile Neutropenia
Background: The optimal frequency of repeat blood cultures in persistent febrile neutropenia (FN) remains unknown. This study aimed to identify opportunities for blood culture diagnostic stewardship in persistent FN. Methods: This was a retrospective cohort study of patients with hematology/oncology diagnoses and an FN episode lasting >3 days. Generalized estimating equation logistic regression models were used to evaluate risk factors for new bloodstream infection (BSI) after FN day 3. Results: Among 620 patients, the median FN duration was 5 days, with a median of 12 blood culture bottles collected per patient. On FN day 1, 25% of patients had a positive blood culture; on FN days 2–9, <5% of patients per day had a new organism isolated. Among 31 new organisms isolated after FN day 3, 8 (26%) were contaminants. Of 503 patients with ≥1 blood culture collected after FN day 3, 19 (4%) had a new BSI after FN day 3. FN onset in the peri–hematopoietic cell transplant period (from day −7 to day +30) was associated with lower odds of new BSI after FN day 3 (odds ratio, 0.18 [95% confidence interval, .04–.71]; P = .01). Thirty-six patients died within 30 days after FN day 3, including 4 with a new BSI after FN day 3; 1 death was attributable to BSI after FN day 3. Conclusions: Detection of new BSIs after FN day 3 was uncommon, demonstrating the low diagnostic yield of repeat blood cultures after FN day 3. FN episodes in the peri–hematopoietic cell transplant period may be a potential focus for blood culture diagnostic stewardship initiatives.
- 20 January 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e826-e834
Open AccessDiagnostic Yield of Repeat Blood Cultures and Risk Factors for Bloodstream Infection in Persistent Febrile Neutropenia
Background: The optimal frequency of repeat blood cultures in persistent febrile neutropenia (FN) remains unknown. This study aimed to identify opportunities for blood culture diagnostic stewardship in persistent FN. Methods: This was a retrospective cohort study of patients with hematology/oncology diagnoses and an FN episode lasting >3 days. Generalized estimating equation logistic regression models were used to evaluate risk factors for new bloodstream infection (BSI) after FN day 3. Results: Among 620 patients, the median FN duration was 5 days, with a median of 12 blood culture bottles collected per patient. On FN day 1, 25% of patients had a positive blood culture; on FN days 2–9, <5% of patients per day had a new organism isolated. Among 31 new organisms isolated after FN day 3, 8 (26%) were contaminants. Of 503 patients with ≥1 blood culture collected after FN day 3, 19 (4%) had a new BSI after FN day 3. FN onset in the peri–hematopoietic cell transplant period (from day −7 to day +30) was associated with lower odds of new BSI after FN day 3 (odds ratio, 0.18 [95% confidence interval, .04–.71]; P = .01). Thirty-six patients died within 30 days after FN day 3, including 4 with a new BSI after FN day 3; 1 death was attributable to BSI after FN day 3. Conclusions: Detection of new BSIs after FN day 3 was uncommon, demonstrating the low diagnostic yield of repeat blood cultures after FN day 3. FN episodes in the peri–hematopoietic cell transplant period may be a potential focus for blood culture diagnostic stewardship initiatives.